AgingResearch.NewsJoin free

Oruka Therapeutics

CompanyUnited States

Oruka Therapeutics develops 2 assets, the furthest preclinical (ORKA-001 in plaque psoriasis). Mostly antibody acting on IL23A, IL17A and IL17F; based in the United States.

2
Assets
Furthest stage
Preclinical
Raised
$880M
0
Trials
0
Signals

Pipeline

2

  • ORKA-001

    Neutralizes IL-23 to inhibit inflammatory signaling.

    Preclinical, Antibody, IL23A, plaque psoriasis, psoriatic arthritis

  • ORKA-002

    Targets IL-17A and IL-17F to inhibit inflammatory signaling.

    Preclinical, Antibody, IL17A, IL17F, plaque psoriasis, psoriatic arthritis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Funding rounds and grants2
  • Deals1
  • Signals1
  • Similar companies6

Intelligence